### UNITED STATES PATENT AND TRADEMARK OFFICE

\_\_\_\_\_

## BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVEN PHARMACEUTICALS, INC., NOVEN THERAPEUTICS, LLC, and HISAMITSU PHARMACEUTICAL CO., INC.

Petitioner

v.

# NOVARTIS PHARMACEUTICAL CORPORATION Patent Owner

Case IPR2014-00550 Patent 6,335,031

Mailed: April 15, 2014

Before PATRICK E. BAKER, Trial Paralegal

# NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE

The petition for *inter partes* review in the above proceeding has been accorded the filing date of April 2, 2014.



Administrative Patent Judge Scott E. Kamholz has been designated to manage the proceeding. 37 C.F.R. § 42.5.

Patent Owner may file a preliminary response to the petition no later than three months from the date of this notice. The preliminary response is limited to setting forth the reasons why the requested review should not be instituted. Patent Owner may also file an election to waive the preliminary response to expedite the proceeding. For more information, please consult the Office Patent Trial Practice Guide, 77 Fed. Reg. 48756 (Aug. 14, 2012), which is available on the Board Web site at <a href="http://www.uspto.gov/PTAB">http://www.uspto.gov/PTAB</a>.

Patent Owner is advised of the requirement to submit mandatory notice information under 37 C.F.R. § 42.8(a)(2) within 21 days of service of the petition.

The parties are encouraged to use the heading on the first page of this Notice for all future filings in the proceeding.

The parties are advised that under 37 C.F.R. § 42.10(c), recognition of counsel *pro hac vice* requires a showing of good cause. The parties are authorized to file motions for *pro hac vice* admission under 37 C.F.R. § 42.10(c). Such motions shall be filed in accordance with the "Order -- Authorizing Motion for *Pro Hac Vice* Admission" in Case IPR2013-00639, Paper 7, a copy of which is available on the Board Web site under "Representative Orders, Decisions, and Notices."

The parties are reminded that unless otherwise permitted by 37 C.F.R. § 42.6(b)(2), all filings in this proceeding must be made electronically in the Patent Review Processing System (PRPS), accessible from the Board Web site at <a href="http://www.uspto.gov/PTAB">http://www.uspto.gov/PTAB</a>. To file documents, users must first obtain a user ID and password by registering with PRPS. Information



Case IPR2014-00550 Patent 6,335,031

regarding how to register with and use PRPS is available at the Board Web site.

If there are any questions pertaining to this notice, please contact Patrick E. Baker at 571-272-6192 or the Patent Trial and Appeal Board at 571-272-7822.

#### PETITIONER:

Steven J. Lee Cynthia Lambert Hardman KENYON & KENYON LLP slee@kenyon.com chardman@kenyon.com

### PATENT OWNER:

NOVARTIS AG Lichtstrasse 35 CH-4056 Basel, Switzerland

LTS LOHMANN THERAPIE-SYSTEME AG Lohmannstraße 2, D-56626 Andernach, Germany

NOVARTIS PHARMACEUTICAL CORPORATION Intellectual Property Department One Health Plaza 101/2 East Hanover, NJ 07936-1080

